Uveal Melanoma Treatment Market is expected to Hit US$ 2.7 billion by 2033 | Major Companies - Delcath Systems, Inc., Immunocore, Ltd., Eli Lilly and Company, iOnctura SA

AI Briefing

• – Uveal Melanoma Treatment Market expected to reach $2.7 billion by 2033, key players include Delcath Systems, Immunocore, and Eli Lilly, with the market growing driven by increasing incidence of uveal melanoma and advancements in treatments
• – Delcath Systems' novel photodynamic therapy and Immunocore's checkpoint inhibitors among major treatment approaches
• – Market growth hindered by high treatment costs, patent expirations, and competition from emerging players